カナダの研究者らによって、皮膚がん(メラノーマ)に対して、単純ヘルペスウイルス1型を用いた免疫療法(Talimogene laherparepvec :T-VEC)の第III相試験が行われ、生存期間の延長などの効果が確認されたと報告されました。予後の悪いメラノーマの新たな治療法になると期待されています。論文は5月26日のJournal of Clinical Oncologyに掲載されました。この件に ついての海外専門家コメントをお送りします。





Robert H.I. Andtbacka et al.,‘Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma’ the Journal of Clinical Oncology


Prof Dorothy Bennett

Head of the Molecular Cell Sciences Research Centre and Professor of Cell Biology, St George's, University of London



“There is currently quite a bewildering array of ongoing trials of new therapies and combinations of new and/or old therapies for malignant melanoma (the most dangerous type of skin cancer).

“This paper reports a trial of another new agent, a herpes virus carrying a gene for the protein GM-CSF, which can stimulate the immune system to attack the cancer. The virus is designed to infect cancer cells and cause them to make GM-CSF, but is modified so that it does not reproduce and infect more cells, nor cause any disease itself.  Significant benefit to patients is reported.

“The question many oncologists would ask is, how does this therapy compare with the other new melanoma immunotherapies such as anti-PD1 and anti-CTLA4 antibodies?  Or with the new small-molecule agents such as BRAF and MEK inhibitors?

“However this question cannot be answered, because this agent was tested in a specific subset of patients “with less advanced cancers” as the press release puts it.  They had to have melanoma nodules amenable to injection, and there was a limit on the number and type of other melanoma nodules around the body.  The effects of the other mentioned therapies on this set of patients have not been assessed.   Instead, the researchers compared the virus treatment to injections of GM-CSF itself, known to have rather little benefit.

“Moreover the trial was open-label rather than single or double-blind, leading to possible loss of objectivity.
“Overall the findings seem interesting but not earth-shattering, in the context of current therapies for melanoma.  However there may well be future value in testing this type of agent in combination with other therapies, as a qualitatively new approach.”

Prof Leonard Seymour

Professor of Gene Therapies, University of Oxford



“This T-Vec study shows powerful stimulus of an anticancer immune response in patients with melanoma skin cancer. Increasingly we understand that cancer is characterised by suppression of the immune system within tumour deposits, meaning that cancer vaccines have struggled to create useful responses. However T-Vec appears to be able to overcome this suppression within the injected tumour masses and mediates stimulation of an effective anticancer response. There is also evidence of significant tumour shrinkage in 15% of evaluable (non-injected) tumour masses, suggesting a level of systemic immunisation for this type of cancer.

“The next step will be to develop oncolytic virus vaccines that can be given intravenously to reach all metastatic tumour deposits, allowing the same vaccine effects in all tumour growths – at this stage it’s very promising that this appears to have positive results for melanoma skin cancer, but we need further research to see whether it could be relevant to other cancers too.

“This study represents a culmination of many years of research into oncolytic viruses as cancer-specific therapeutics. Oncolytic viruses combine four crucial advances compared to conventional cancer treatments:

1. They amplify themselves selectively within tumour cells, increasing the amount of therapeutic agent locally without causing high levels in the bloodstream. This maximises anticancer activity and minimises unwanted side effects.

2. Their selectivity for cancer cells depends on the cancer phenotype and can be far more selective than traditional chemotherapy agents that merely target cells that are proliferating.

3. Oncolytic viruses can kill cells actively (not always dependent on cellular pathways of apoptosis), providing the possibility of a more inflammatory death pathway that can be used to produce a cancer vaccine.

4. They can encode biologics for expression selectivity within the tumour (in this case a molecule called GM CSF). This provides a whole new approach to using novel biological therapeutics that are often too toxic to be given to patients as proteins, but should be very effective when produced by the patient’s own tumour cells in situ.

“The oncolytic virus field has been buzzing in recent years, with hundreds of scientists involved worldwide, and the next international event will be held in Boston in two weeks’ time (http://ovcboston.com/).
“Oncolytic virus vaccines should synergise perfectly with the other big recent advance in cancer therapy – ‘immune checkpoint inhibitors’. Whereas oncolytic vaccines can stimulate an anticancer immune response, checkpoint inhibitors potentiate the ability of the immune system to respond. The combination of T-Vec with anti-CTLA4 has already shown astonishing results (Puzanov et al.,http://meetinglibrary.asco.org/content/128142-144).”

*Prof Leonard Seymourは、オックスフォード大学でウイルス由来のがん遺伝子治療の研究をしています。彼は、静脈経由ではなく、直接腫瘍に注入するワクチンを開発しているPsiOxus株式会社のコンサルタントをしており、研究費をもらっています。






サイエンス・メディア・センターでは、このような情報をメールで直接お送りいたします。ご希望の方は、下記リンクからご登録ください。(登録は手動のため、反映に時間がかかります。また、上記下線条件に鑑み、広義の「ジャーナリスト」と考えられない方は、登録をお断りすることもありますが御了承下さい。ただし、今回の緊急時に際しては、このようにサイトでも全ての情報を公開していきます)【メディア関係者データベースへの登録】 http://smc-japan.org/?page_id=588


○ 私的/商業利用を問わず、記事の引用(二次利用)は自由です。ただし「ジャーナリストが社会に論を問うための情報ソース」であることを尊重してください(アフィリエイト目的の、記事丸ごとの転載などはお控え下さい)。

○ 二次利用の際にクレジットを入れて頂ける場合(任意)は、下記のいずれかの形式でお願いします:
・一般社団法人サイエンス・メディア・センター ・(社)サイエンス・メディア・センター
・(社)SMC  ・SMC-Japan.org

○ この情報は適宜訂正・更新を行います。ウェブで情報を掲載・利用する場合は、読者が最新情報を確認できるようにリンクをお願いします。


一般社団法人 サイエンス・メディア・センター(日本) Tel/Fax: 03-3202-2514